Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.
Journal: Science translational medicine
Published: August 05, 2026
Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey.
Journal: Journal of neuro-oncology
Published: April 24, 2026
Reproductive health considerations for IDH-mutant glioma patients considering IDH inhibitor therapy: A retrospective cohort study.
Journal: Neuro-oncology practice
Published: December 29, 2025
Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review.
Journal: Cancers
Published: July 11, 2025
Factors associated with cognitive impairment in long-term IDH-mutant glioma survivors.
Journal: Journal of neuro-oncology
Published: June 12, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomes.
Journal: Neuro-oncology advances
Published: February 06, 2025
Ready to INDIGO: Vorasidenib Ushers in the Era of Isocitrate Dehydrogenase Inhibition in Low-Grade Glioma.
Journal: International journal of radiation oncology, biology, physics
Published: October 16, 2023
Diagnostic and Therapeutic Updates in Leptomeningeal Disease.
Journal: Current oncology reports
Published: May 03, 2023
Response to "Polyradiculitis Complicating SARS-CoV-2 Vaccinations is Not Infrequent".
Journal: The Neurohospitalist
Published: April 17, 2023
A Single-Institution Retrospective Series of SARS-CoV-2 Infection in Adult Glioma Patients.
Journal: Case reports in oncology
Published: March 08, 2023
Last Updated: 09/26/2026